Last Updated: 2/19
Share or print this information to talk to your doctor about this trial.
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies.
Interventions
Phase
2
Status
Recruiting
Conditions
Ages
18 and older
Sexes
All
Apellis Investigational Site
Stanford, CA 94305
Aurora, CO 80045
Denver, CO 80205
Washington, DC 20037
Coral Gables, FL 33134
Atlanta, GA 30322
Louisville, KY 40203
Shreveport, LA 71101
Takoma Park, MD 20912
Kansas City, MO 64111
Bronx, NY 10461
Valhalla, NY 10595
Wilmington, NC 28401
Memphis, TN 38103
Alexandria, VA 22304
Chesapeake, VA 23320
Wauwatosa, WI 53226
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
Federico Grossi, MD, PhD | 617-977-5701
clinicaltrials@apellis.com
www.apellis.com
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
To ensure you receive the best user experience, our site uses cookies to store information in your browser.
To find out more, view our Privacy Policy.
Continued use of this site indicates you have accepted this policy.